Cancer
Conditions
Keywords
cancer, liquid biopsy, cell-free DNA (cfDNA), microRNA (miRNA), early detection
Brief summary
PROMISE is a multi-center, prospective and proof of concept study aimed to evaluate the performance of 3 prototype assays of cell-free DNA (cfDNA) mutation, cfDNA methylation and microRNA (miRNA) expression in early detection of multi-cancer. Assay(s) will be selected for further development. The study will enroll approximately 2035 participants, including participants with cancers and healthy participants.
Detailed description
Blood samples will be prospectively collected from cancer patients and non-cancer individuals. Targeted cell-free DNA (cfDNA) methylation panel of \ 490,000 CpG sites, a 168-gene mutation panel and 16 proteins will be applied. Participants will be stratified by age and clinical status and split into the training and the testing sets. The multi-cancer detection blood test models were developed on training set and validated on testing set.
Interventions
Blood collection and multi-cancer early detection test
Sponsors
Guangzhou Burning Rock Dx Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Inclusion criteria
for Cancer Arm Participants: * Ability to provide a written informed consent * 40-75 years old * Ability to comply with study procedures * Confirmed diagnosis or suspicious cases of one of the 9 types of cancers within 42 days prior to study blood draw. * No prior anti-cancer therapy (local or systematic) prior to study blood draw
Exclusion criteria
for Cancer Arm Participants: * Pregnancy or lactating women * Recipients of organ transplant or prior non-autologous (allogeneic) bone marrow transplant or stem cell transplant * Recipients of blood transfusion within 7 days prior to study blood draw * Recipients of any anti-cancer therapy within 30 days prior to study blood draw, due to diseases other than cancer * Known prior diagnosis of malignancies, other current malignant diseases or multiple primary tumors * No confirmed diagnosis of cancer by histopathological or radiological assessments within 42 days of study blood draw, or diagnosis of a benign disease or precancerous lesions by histopathological assessments, or inability to characterize whether the lesion is malignant or benign Inclusion Criteria for Healthy Arm Participants: * Ability to provide a written informed consent * 40-75 years old * No cancer-related symptoms or discomfort within 30 days prior to study blood draw * Ability to comply with study procedures * No clinically significant finding by laboratory tests and radiology examinations
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of early detection of cancers and Tissue of origin (TOO) accuracy of 3 assays of cfDNA mutation, cfDNA methylation and miRNA expression when specificity was 90%, 95% or 98% in healthy participants | 9 months | Sensitivity of early detection of cancers and Tissue of origin (TOO) accuracy of 3 assays of cfDNA mutation, cfDNA methylation and miRNA expression when specificity was 90%, 95% or 98% in healthy participants |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity, specificity and TOO accuracy of an assay of cfDNA mutation in various types of cancer in different stages | 9 months | Sensitivity, specificity and TOO accuracy of an assay of cfDNA mutation in various types of cancer in different stages |
| Sensitivity, specificity and TOO accuracy of an assay of cfDNA methylation in various types of cancer in different stages | 9 months | Sensitivity, specificity and TOO accuracy of an assay of cfDNA methylation in various types of cancer in different stages |
| Sensitivity, specificity and TOO accuracy of an assay of miRNA expression in various types of cancer in different stages | 9 months | Sensitivity, specificity and TOO accuracy of an assay of miRNA expression in various types of cancer in different stages |
| Sensitivity, specificity and TOO accuracy of combined assays of cfDNA mutation, cfDNA methylation and/or miRNA expression in early detection of cancers | 9 months | Sensitivity, specificity and TOO accuracy of combined assays of cfDNA mutation, cfDNA methylation and/or miRNA expression in early detection of cancers |
Countries
China
Outcome results
None listed